NCT lookup

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

* Has histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology
* Has prostate cancer progression while on androgen deprivation therapy (ADT) (or post bilateral orchiectomy) within 6 months before Screening
* Has current evidence of distant metastatic disease
* Has received prior treatment with 1 or 2 androgen receptor pathway inhibitors (ARPIs) and progressed during or after treatment
* Participants receiving bone resorptive therapy (including, but not limited to bisphosphonate or denosumab) must have been on stable doses for ≥4 weeks before allocation/randomization
* An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 assessed within 10 days before allocation/randomization
* Has prior treatment with poly-ADP-ribose polymerase inhibitors (PARPi) if indicated by local approved regimen or were deemed ineligible to receive PARPi by the investigator

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

* Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use (except for a history of radiation pneumonitis that did not require steroids), current ILD, clinical or radiographic suspicion of ILD for which the diagnosis of ILD cannot be ruled out
* Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
* Uncontrolled or significant cardiovascular disease
* History of pituitary dysfunction
* Poorly controlled diabetes mellitus
* History or current condition of adrenal insufficiency (eg, Addison's disease)
* Has received prior treatment with taxane-based chemotherapy agent for metastatic castration-resistant prostate cancer (mCRPC).
* Chronic steroid treatment (dose of \>10 mg daily prednisone equivalent), except for low-dose inhaled steroids (for asthma/chronic obstructive pulmonary disease), topical steroids (for mild skin conditions), or intra-articular steroid injections
* Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids
* Known additional malignancy that is progressing or has required active treatment within the past 3 years
* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
* Active autoimmune disease that has required systemic treatment in the past 2 years
* History of allogeneic tissue/solid organ transplant

• Los Angeles, California, United States
• Orange, California, United States
• San Francisco, California, United States
• Washington D.C., District of Columbia, United States
• Ann Arbor, Michigan, United States
• New York, New York, United States
• Pittsburgh, Pennsylvania, United States
• Germantown, Tennessee, United States
• Seattle, Washington, United States
• Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
• La Rioja, Argentina
• Macquarie University, New South Wales, Australia
• Natal, Rio Grande do Norte, Brazil
• Porto Alegre, Rio Grande do Sul, Brazil
• Porto Alegre, Rio Grande do Sul, Brazil
• Bragança Paulista, São Paulo, Brazil
• Ribeirão Preto, São Paulo, Brazil
• São José do Rio Preto, São Paulo, Brazil
• São Paulo, São Paulo, Brazil
• São Paulo, Brazil
• São Paulo, Brazil
• Vancouver, British Columbia, Canada
• Toronto, Ontario, Canada
• Toronto, Ontario, Canada
• Montreal, Quebec, Canada
• Sherbrooke, Quebec, Canada
• Talca, Maule Region, Chile
• Santiago, Region M. de Santiago, Chile
• Santiago, Region M. de Santiago, Chile
• Santiago, Region M. de Santiago, Chile
• + 52 more on CT.gov